A randomized study for children and adolescents with migraine: acute treatment.

• Migraine affects people of all ages
• Migraine may be an inflammatory response to various triggers
• This study will focus on migraines in pediatric and adolescent patients
• There are two types of medication to treat migraines: preventative and rescue
• This study drug is looking at the efficacy of a rescue medication to treat migraine

Study Benefits

• The commonly used medications for stopping a migraine attack include pain medications (ibuprofen, acetaminophen, naproxen) and triptans (sumatriptan/lmitrex, rizatriptan/Maxalt, zolmitriptan/Zomig).
• Although these medications work well for some, they do not work well for all
• Therefore, the study aims to investigate the effectiveness of the study drug in children with migraine
• Ubrogepant (Ubrelvy) is a novel CGRP receptor blocker
• Based on evidence that CGRP plays a role in the onset of pediatric migraine, the study medication helps to block the production of CGRP and therefore minimize the onset of acute migraine

Study Volunteers Must Meet the Following Criteria

• 6 -17 years of age
• Male/Female
• Must have a history of migraine with or without aura for at least 6 months

Study Participant Expectations

• Must come to site during a migraine attack

Cost

• There is no cost to participate
• Compensated up to $75 for participation
• 3 office visits